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Abstract
Fifty years ago, Hans Ussing described the mechanism by which ions are actively transported across frog skin. Since then, an enormous
amount of effort has been invested in determining the cellular and molecular specifics of the transport mechanisms and their regulatory
pathways. Ion transport in high-resistance epithelia is regulated by a variety of hormonal and non-hormonal factors. In vertebrates, steroid
hormones such as mineralocorticoids, glucocorticoids and estrogens are major regulators of ion and water transport and hence are central to
the control of extracellular fluid volume and blood pressure. Steroid hormones act through nuclear receptors to control the transcriptional
activity of specific target genes, such as ion channels, ion transporters and ion pumps. These effects are observed after a latency of several
hours and can last for days leading to cellular differentiation that allows a higher transport activity. This pathway is the so-called genomic
phase. However, in the past 10 years, it has become apparent that steroid hormones can regulate electrolyte and water transport in tight
epithelia independently of the transcription of these ion channels and transporters by regulating ion transporter activity in a non-genomic
fashion via modulation of various signal transduction pathways. The molecular mechanisms underlying the steroid hormone-induced
activation of signal transduction pathways such as protein kinase C (PKC), protein kinase A (PKA), intracellular calcium, intracellular pH
and mitogen-activated protein kinases (MAPKs) and how non-genomic activation of these pathways influences epithelial ion transport will
be discussed in this review.
D 2002 Published by Elsevier Science B.V.
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1. Introduction
Some of the first studies of rapid responses to steroid
hormones in epithelia were performed on frog skin, which
showed rapid ( < 1 min) activation of basolateral K+ recy-
cling and Na+–H+ exchange following exposure to aldos-
terone. These rapid ‘non-genomic’ effects are also observed
in other Na+- and Cl-transporting epithelia such as human
sweat gland and colon in response to physiological concen-
trations of aldosterone and estradiol. In this paper, we will
describe the signal transduction pathways [Ca2 +, protein
kinase C (PKC), protein kinase A (PKA), and mitogen-
activated protein kinases (MAPKs)] involved in the rapid
responses to aldosterone and estradiol and discuss their
physiological impact.
Understanding the relationship between rapid non-
genomic effects of steroid hormones on intracellular second
messengers and their subsequent cellular effects on ion
transport targets requires an integrative approach in which
both measurement of the cytosolic transduction processes
and the macroscopic effects are determined simultaneously
in whole tissue under physiological conditions. Aldosterone
is the most important mineralocorticoid hormone released
from the adrenal glands, regulating solute reabsorption in
epithelia such as distal colon and kidney [1], acting in both a
rapid and delayed manner to influence transport, that is, via
both non-genomic and genomic pathways. Similarly, 17h-
estradiol (E2), in addition to its primary functions to control
the development of female reproductive organs, also regu-
lates transepithelial transport by a rapid non-genomic mech-
anism [2,3]. Studies from our laboratory have demonstrated
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rapid ( < 1 min) non-genomic activation of PKC activity
(PKCa for aldosterone, PKCa and PKCy for E2), MAP
kinase activity, a PKC-dependent Ca2 + entry and a PKCa-
dependent effect on Na+–H+ exchange and K+ recycling by
mineralocorticoids and E2 in distal colon [2,4–8]. Rapid
effects of E2 are female gender specific and insensitive to
inhibitors of the classical estrogen receptor. Physiological
concentrations of E2 reduced both basal and secretagogous-
induced Cl secretion [3]. The antisecretory effect of E2 is
sensitive to PKC inhibition, intracellular Ca2 + chelation, is
female gender specific and insensitive to inhibitors of the
classical ER. However, E2-induced activation of MAPK
proceeds via an ER-dependent pathway. The primary ion
transport target of the non-genomic signal transduction
cascade elicited by aldosterone and E2 in epithelia is the
Na+–H+ exchanger. Both aldosterone and E2 produced a
PKCa sensitive intracellular alkalinization within 1 min of
hormone addition [8]. An increased intracellular pH up-
regulates a basolateral ATP-dependent K+ channel, which is
involved in K+ recycling to maintain an electrical driving
force for Na+ absorption, while inhibiting a Ca2 +-dependent
K+ channel, which generates the charge balance for Cl
secretion. The non-genomic response to aldosterone and E2
in distal colon appears to enhance the capacity for absorp-
tion while down-regulating the potential for secretion [9].
These observations link rapid non-genomic activation of
second messengers with a gender-specific physiological
effect in the whole tissue. Aldosterone and E2 differ in
their protein kinase signal transduction and both hormones
stimulate specific PKC isoforms indicating both common
and divergent signalling systems for salt-retaining steroid
hormones [2,6,8]. The physiological function of non-
genomic effects of aldosterone and E2 is to shift the balance
from net secretion to net absorption in a pluripotential
epithelium. In this review, we will focus initially on molec-
ular mechanisms of steroid hormone-induced activation of
PKC isoforms and MAPK before discussing the rapid
effects of these hormones on ion transport in epithelial cells.
2. Rapid effects of steroid hormones on signal
transduction pathways
2.1. Rapid action of steroid hormones on PKC
PKC comprises a large family of proteins with multiple
isoforms—which can be divided into three subgroups,
classical PKC (cPKC) isoforms (a, h1, h2, g), novel PKC
(nPKC) isoforms (y, q, D, u, A) and atypical PKC (aPKC)
isoforms (~ , E), based on different activator/cofactor
requirements. The various PKC isoforms exhibit subtly
different kinetics, specific patterns of tissue distribution
and intracellular localisation, differing modes of activation
and distinct behaviour during the cellular response [10].
Many studies have been performed to identify specific roles
for each PKC isoform. It has been proposed that some
isoforms may play a role in regulating membrane functions
such as receptor down-regulation, modulation of ion chan-
nels and pumps and membrane phospholipid hydrolysis
leading to the generation of lipid mediators [10].
Rapid non-genomic stimulation of PKC activity has been
demonstrated by various steroid hormones and in numerous
cell types—aldosterone [4,5,11], E2 [4,12], glucocorticoids
[13], adrenal androgen—dehydroepiandrosterone [14],
1,25(OH)2 vitamin D3 [15]. Similarly, many rapid steroid
hormone effects are mediated by PKC, for example, aldos-
terone [4,5,7,16 – 18], estradiol E2 [3,6,12,19 – 21],
1,25(OH)2 vitamin D3 [15].
Studies from various laboratories have also demonstrated
direct binding and activation of different PKC isoforms by a
variety of steroid hormones. Slater et al. [22] and Stubbs et
al. [23] observed direct activation of rat brain PKC (a, h and
g) and PKC-a, -g and -q isoforms by 1,25(OH)2 vitamin D3
at physiological concentrations. Results of these studies
demonstrated that 1,25(OH)2 vitamin D3 binds to PKC at
the activator binding site and induces PKC activity in a
manner resembling the effect of DAG and phorbol esters.
The adrenal androgen, dehydroepiandrosterone, has also
been shown to bind to purified PKC from rat brain, con-
taining PKC a, h and g isoforms and also to atypical PKC~
[14]. Similar results have been observed with glucocorti-
coids and in these studies, binding of the steroid to the
regulatory subunit of PKC was demonstrated [24,25]. Doo-
lan et al. [6] have also demonstrated direct and specific
activation of human recombinant PKCa by physiological
concentrations of aldosterone and E2 (Fig. 1). Estradiol also
directly and specifically stimulated PKC-y activity (Fig 1).
Current evidence therefore, points to PKC isoforms as non-
genomic receptors for rapid responses to steroids [6,22,23].
2.2. Rapid non-genomic effects of mineralocorticoids on
PKC activity
Aldosterone has been shown to exert rapid non-genomic
effects on PKC activity in vascular smooth muscle cells
(VSMCs) [11], mammalian distal colonic epithelium [4,5]
and a DAG-dependent PKC activation in cultured kidney
cells [17]. In contrast, in neonatal rat cardiomyocytes,
aldosterone rapidly represses PKC [26].
Various studies indicate that aldosterone non-genomi-
cally activates the Ca2 +-sensitive PKC isoform, PKCa. In
VSMCs, aldosterone induced a rapid activation and trans-
location of PKCa from cytosolic to membrane fractions
[11]. Doolan et al. [6] have demonstrated a direct and
specific activation of human recombinant PKCa, by phys-
iological concentrations of aldosterone, in a cell-free assay
system (Fig. 1). However, no stimulatory effect of other
PKC isoforms known to be present in distal colonic epi-
thelium, PKCy, PKCq and PKC~ [27], was observed in the
presence of aldosterone (0.01–10 nM). The results of this
study point to the PKCa isoform as a candidate non-
genomic receptor for rapid responses to aldosterone.
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Many rapid non-genomic aldosterone effects are medi-
ated by PKC, for example, stimulation of human colonic
KATP channel and Na
+–H+ exchanger [7], activation of
Na+–H+ exchanger in VSMCs [16], stimulation of H+
conductive influx in renal epithelial cells [17] and increases
in [Ca2 +]i in T84 colonic epithelial cells, mammalian distal
colonic epithelium and M-1 cortical collecting duct cells
[4,5,18,28] (Fig. 1).
Conflicting reports exist as to the rapid effects of
aldosterone on intracellular cAMP levels and PKA activity.
Christ et al. [29] have demonstrated a 2-fold increase in
intracellular cAMP levels in VSMCs at physiological aldos-
terone concentrations. In contrast, however, no stimulation
of the PKA pathway was observed by aldosterone in rat
distal colonic epithelium [6].
Rapid effects of aldosterone on free intracellular calcium
[Ca2 +]i have been demonstrated in VSMCs, porcine aortic
endothelial cells [30,31], T84 colonic epithelial cells, human
and rat distal colonic epithelium [4,5,18] and M-1 cortical
collecting duct cells [28] with the Ca2 + source differing
between various cell types. These rapid responses appear to
be mineralocorticoid specific since glucocorticoid hormones
(hydrocortisone, dexamethasone) either failed to produce a
response or exhibited a very small response at supraphysio-
logical doses.
2.3. Interaction between PKC and estrogens
The first direct evidence that E2 modulates PKC was
obtained by Drouva et al. [32]. This study demonstrated that
estradiol implants in ovariectomised rats significantly
increased Ca2 + and phospholipid-dependent PKC in both
soluble and particulate fractions of anterior pituitary. The
stereoisomer 17a-estradiol was without effect. Recent stud-
Fig. 1. Signal transduction pathways for non-genomic action of steroid hormones. Both aldosterone and estradiol directly stimulate PKCa activity resulting in
activation of NHE and intracellular alkalinization followed by an inhibition of KCa channel activity. Estradiol directly and specifically stimulates PKCy activity.
PKCy activates adenylyl cyclase activity resulting in an increase in PKA activity, followed by an inhibition of KCa channel activity. Both PKCy and PKA are
required for calcium entry. Inhibition of KCa channels reduces potassium recycling in the basolateral membrane reducing the driving force for chloride
secretion.
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ies have demonstrated an up-regulation of PKCy expression
in the rat and rabbit corpus luteum by estrogen [33–35]. In
contrast, however, E2 treatment of the MCF-7 breast cancer
cell line resulted in a significant decrease in PKCy protein
and mRNA expression in a time- and dose-dependent
manner [36]. These authors suggest that the differential
ability of E2 to regulate PKCy expression could be a result
of differential signalling through either ERa or ERh.
Lahooti et al. [37] report that PKCy participates in the
signalling pathways that lead to ER phosphorylation. These
studies therefore indicate a role for PKC in the biological
response to estrogen.
One of the earliest reports of rapid non-genomic effects
of estradiol was in 1969 by Szego and Davis [38]. In this
study, estrogen treatment of rats in vitro resulted in an acute,
very rapid elevation of uterine cAMP. Estradiol has also
been shown to exhibit rapid non-genomic effects in various
cell types on (i) adenylyl cyclase activity and cAMP
production in rat pulmonary VSMCs, human coronary
artery endothelium and rat uterine cells and MCF-7 cells
[39–41], (ii) PKA activity in muscle and mammalian distal
colon [6,42], (iii) PKC activity in mammalian distal colon
and chondrocytes [4,5,12,43], (iv) Ca2 + (with the Ca2 +
sources differing in various cell types) in female rat osteo-
blasts, chicken and pig granulosa cells, single rat hepato-
cytes, mammalian distal colonic crypts and rat duodenal
enterocytes, [6,20,44–47] and in human monocytes via the
activation of an estrogen surface receptor [48], and (v)
targeting ion transport pathways such as pumps and chan-
nels in mammalian distal colonic epithelium [3,9,49]. Both
PKC and PKA have been shown to play a role in E2-
dependent Ca2 + responses in many tissue types such as
duodenal enterocytes, mammalian distal colon and primary
rabbit proximal tubule cells [6,20,21,47] indicating multiple
signalling pathways which influence E2-dependent changes
in [Ca2 +]i.
E2 has been shown to activate specific PKC isoforms in a
non-genomic manner. In both growth zone and resting zone
chondrocytes, E2 rapidly activated and translocated PKCa
from cytosolic to membrane fractions. The stereoisomer,
17a-estradiol, was without effect [43]. E2 has also been
shown to directly and specifically stimulate PKCy activity
in a cell-free assay system (Fig. 1). Other steroid hormones
such as aldosterone and 17a-estradiol were without effect
on PKCy activity. E2 also rapidly and directly activated
PKCa activity in a concentration-dependent manner. How-
ever, E2 exhibited no stimulatory effect on other PKC
isoforms known to be present in distal colonic epithelium,
PKCq and PKC~ [2,6]. Studies from our laboratory have
also demonstrated an E2-induced PKCy-specific activation
of PKA activity in rat distal colonic epithelium (Fig. 1).
Therefore, the cytosolic protein responsible for rapid non-
genomic E2-PKA activation is the Ca2 +-independent, phos-
pholipid-dependent PKCy isoform [2,6]. The results of this
study point to the PKCy isoform as a candidate non-
genomic receptor for rapid responses to E2.
2.4. Gender-specific rapid non-genomic E2 effects
Studies from many laboratories have demonstrated gen-
der-specific non-genomic responses to E2. Sylvia et al. [43]
have shown that E2 stimulated PKC activity in a sex-
dependent manner in rat costochondral chondrocyte cul-
tures. Studies from our laboratory have shown E2-stimu-
lated, PKC-sensitive female gender-specific effects on PKA
activity, intracellular Ca2 + concentration, intracellular pH
and forskolin-induced chloride secretion in rat distal colonic
epithelium [3,6,8]. The reason for this gender specificity is
as yet unknown. One possible explanation is that there may
be different PKC isoform distribution between male and
female tissue. Studies performed in rat liver have in fact
shown both gender specific and developmental differences
in PKC isoform expression with levels of both PKCa and
PKCy being higher in females vs. males [50].
2.5. Common and divergent signalling pathways for rapid
effects of aldosterone and estradiol
Aldosterone and E2 differ in their protein kinase signal
transduction and both hormones stimulate specific PKC
isoforms. Isozyme-specific properties such as substrate
specificities, subcellular localisation, activation require-
ments and rates of down-modulation suggest that different
PKC isoforms may perform unique cellular functions.
Initially, there appeared to be a common stimulatory signal-
ling pathway for rapid non-genomic responses to aldoster-
one and estradiol, that is, PKC. Our recent results [6] now
suggest that these steroid hormones stimulate different PKC
isozymes with aldosterone stimulating PKCa selectively
and estradiol stimulating both PKCa and PKCy. These
properties confer both common and divergent signalling
pathways for salt-retaining steroid hormones [2,6,8] (Fig. 1).
2.6. Rapid non-genomic activation of extracellular-regu-
lated kinase (Erk) 1/2 by 17b-estradiol
Mitogen-activated protein (MAP) kinases are serine/
threonine kinases that become activated in response to a
diverse array of extracellular stimuli including growth
factors, cytokines, UV irradiation and shear stress [51].
They exert their effects by phosphorylating a wide variety
of cytoplasmic targets and transcription factors. MAPKs can
be subdivided into about five families, three of which, Erk,
jun N-terminal kinase (Jnk) and p38 kinase, have been very
well characterised. In general, mitogenic stimuli such as
growth factors activate the Erk family of MAPKs (com-
posed of two closely related isoforms Erk1 and Erk2) while
stressful stimuli usually activate Jnk and p38 MAPKs. All
MAPKs are the final component of a highly conserved
module of three kinases, known as a MAPK pathway, which
are sequentially activated by phosphorylation [51]. There
exists a degree of cross-talk between the previously men-
tioned PKC family of signalling proteins and the MAPK
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pathway. Specifically, it has been shown that the PKCa
isoform phosphorylates and activates Raf-1, which in turn
leads to downstream activation of Erk1/2 [51]. Similarly, a
recent study has demonstrated that activation of PKCy leads
to phosphorylation/activation of Erk1/2 in intestinal epithe-
lial cells [52].
It has been well established that 17h-estradiol triggers a
rapid (1–10 min) but transient activation of Erk1/2 in a
large number of different cell types and tissues [53–57]. In
our laboratory, we have shown that in vitro treatment of rat
colonic epithelia with physiological concentrations of the
hormone can stimulate a transient activation of Erk1/2
within 1 min (unpublished data). It has also been shown
previously that E2 rapidly activates Erk1/2 in Caco-2 cells, a
human colon carcinoma cell line [58]. Therefore, it is clear
that Erk1/2 in intestinal epithelial cells is responsive to
treatment with estrogen. An exception to the observation
that E2 induces activation of Erk1/2 is VSMCs. In these
cells, hormone treatment actually causes a reduction in basal
levels of Erk1/2 and E2 also acts to inhibit Erk1/2 activation
induced by serum treatment [59]. A possible reason for
these variable effects of E2 on Erk1/2 is discussed below.
2.7. Molecular mechanisms underlying the modulation of
Erk1/2 activity by 17b-estradiol
By employing ER antagonists such as ICI 182,780, the
majority of studies have found that the classical ER is
necessary for hormone-induced activation [53–57]. In our
experiments on isolated rat colonic epithelia (unpublished
results) and on Caco-2 cells [58], ICI 182,780 inhibits
estrogen-dependent activation of Erk1/2, suggesting a key
role for ER. There is evidence in the literature demonstrat-
ing the expression of functional estrogen receptors in normal
intestinal epithelia. Thomas et al. [60] were the first to
conclusively show that epithelial mucosa from male and
female rat duodenum, jejunum, mid-ileum and colon all
express ERa. While they were unable to identify if crypt or
villar epithelial cells from these tissue samples both express
ERa, they demonstrated that IEC-6 cells, which are derived
from small intestinal crypts cells, express ERa and that 17h-
estradiol induces rapid up-regulation of c-fos in IEC-6 cells
[60]. This strongly suggests that, in vivo, pluripotential
crypt cells, which undergo replication and differentiation
into secretory and absorptive epithelial cells in the villus, are
responsive to E2. In a more recent study of normal human
colonic mucosa, expression of ERa and ERh was observed,
with ERh levels in greater abundance than ERa [61].
Immunolocalization experiments also showed ERh staining
in superficial epithelial cells, whereas crypt cells were
negative [61].
Because E2 triggers such a rapid activation of Erk1/2 in
so-varied cell types, many researchers have postulated the
existence of a membrane receptor to which the hormone
binds resulting in a signal transduction process that causes
the activation of the MAPK pathway. In support of this
hypothesis, several groups have shown that the membrane-
impermeable conjugate, E2-BSA, is capable of rapidly
activating signalling pathways [62–64]. On a cautionary
note, however, it has been reported that some preparations
of the conjugate may be contaminated with free hormone
and in addition, experiments have shown that purified E2-
BSA does not bind ER in vitro. This would suggest that the
conjugate does not mimic the biological hormone [65].
The requirement for ER participation in Erk1/2 activation
has led to the hypothesis that the ER itself may be localised
at or near the plasma membrane and be involved in the
signal transduction process. In support of this, Razandi et al.
[66] have shown that overexpression of both ERa and ERh
in CHO cells enables E2 to activate a number of signal
transduction pathways in these cells, including the MAPK
pathway. Moreover, highly purified preparations of plasma
membrane from the transfected cells contain significant
quantities of ER as determined by Western blotting [66].
In addition, immunocytochemical staining of cells with anti-
ER antibodies shows strong binding to plasma membranes
[67]. In a recent experiment on MCF-7 cells, a breast cancer
cell line, treatment with E2 increased anti-ER staining at the
plasma membrane suggesting that hormone treatment may
cause a translocation of ER to the cell membrane [68].
Because neither ERa nor ERh possesses hydrophobic
transmembrane helices necessary for insertion in the lipid
bilayer of the plasma membrane, the receptor may actually
associate with integral plasma membrane proteins. Caveolae
are specialized cholesterol-rich plasma membrane micro-
domains that compartmentalize signal transduction mole-
cules such as membrane receptors and signalling proteins.
They also contain scaffolding proteins that belong to a
family of proteins known as caveolins that associate with
these signal-modulating proteins [69]. Caveolin-1 and -2 are
ubiquitous while caveolin-3 is restricted to muscle cells. It
has recently been established that ER can associate with
either caveolin-1 or -2 in a number of cell types, thereby
localising ER to the caveolar microdomains in close prox-
imity with signalling molecules [70,71]. The effect of E2 on
the association between ER and caveolins is cell-type
dependent, however. In VSMCs, there is little association
between ER and caveolins in the absence of estrogen but
hormone treatment triggers a 3-fold increase in association.
The situation in MCF-7 cells is reversed, with hormone
treatment reducing the strong interaction between ER and
caveolins present in unstimulated cells [71]. These opposing
effects of 17h-estradiol on caveolin/ER association may
explain why the hormone activates Erk1/2 in MCF-7 cells
and inhibits it in VSMCs. Caveolins, while crucial for
assembling signalling complexes, also act to inhibit signal
activation and their dissociation from the signalling com-
plex, as occurs in MCF-7 cells upon E2 treatment, is
necessary for activation of Erk1/2 to occur. Because the
hormone increases the association of caveolin and ER in
VSMCs, signal transduction to Erk1/2 is suppressed [71].
Supporting the proposed role of caveolins in assembling
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signalling complexes, overexpression of caveolin-1 in
MCF-7 cells induces an increased translocation of ER to
the cell surface [71].
Normal intestinal epithelial cells and Caco-2 cells
express either very little or no caveolin-1 and caveolin-2
and rarely exhibit classic plasmalemmal caveolae [72,73].
However, a recent study using immunocytochemical analy-
sis has determined that in normal intestinal epithelia cells
and in T84 cells, an intestinal carcinoma cell line, caveolin-1
staining was most likely localised mainly to the basolateral
plasma membrane [73], the region of the cell that steroid
hormones would encounter in vivo. While it remains to be
investigated, it seems likely that ER may associate with
caveolins at the basolateral membrane of intestinal cells.
While caveolins associate with ER and modulate non-
genomic actions of E2 on Erk1/2, they are not signalling
molecules. However, the localisation of ER in caveolar
structures would permit its association with signalling
proteins situated here. A small number of candidate proteins
have been investigated to date. Src kinase, a tyrosine kinase
normally tethered to the cytoplasmic side of the plasma
membrane, is a key signalling molecule which upon acti-
vation leads to the stimulation of MAPK pathways in many
cell types [74]. Migliaccio et al. [53] have published a
number of key papers investigating the role of Src kinase in
E2-induced activation of Erk1/2. First, they showed that E2
treatment of MCF-7 cells triggers a very rapid activation of
Src and that pharmacological inhibition of Src activity
blocks the activation of Erk1/2 suggesting that Src kinase
lies upstream of Erk1/2. The same group also demonstrated
that Erk1/2 activation by estrogen in Caco-2 cells also
requires prior activation of Src [58]. Second, they demon-
strated that E2 treatment promotes a physical interaction
between Src and both ERa and ERh in MCF-7 cells
resulting in the activation of Src kinase [75]. Mutagenesis
studies revealed that phosphotyrosine 537 in the ligand
binding domain of ER is crucial for ER association with
Src and Src activation by E2 [75]. This implies that the SH2
domain of Src binds to this phosphotyrosine residue on ER
perhaps as a result of a conformational change in the ER
triggered by hormone binding. More recently, another group
has confirmed these findings and has further shown that the
ligand binding domain of ER alone is sufficient to confer
responsiveness to E2 [76]. Src kinase can activate the
MAPK pathway via the adaptor protein Shc. Shc binds to
active Src and acts as a docking site for Grb2 and Sos which
in turn trigger Ras activation leading to the activation of the
MAPK pathway [51]. In a recent paper, it was claimed that
E2 rapidly induces the physical association between ERa
and Shc in MCF-7 cells [68]. This would suggest the ER
can physically interact with both Src and Shc when these
signalling molecules form a complex.
Another putative ER binding protein is the p85 subunit
of phosphatidylinositol 3-OH kinase (PI3K). This signalling
molecule is classically activated by insulin growth factor-1
(IGF-1) binding to its receptor and has numerous down-
stream targets involved in cell proliferation including pro-
tein kinase B (or Akt) and in some cell types, the MAPK
pathway [77]. Recently, it has been shown that E2 rapidly
activates Akt in VSMCs in a PI3K-dependent manner [78].
Moreover, hormone treatment triggers an association
between the catalytic subunit (p85) of PI3K and ERa but
not ERh [78]. Another report also describes the E2-depend-
ent association between ERa (but not ERh) and the IGF-1
receptor which results in the activation of the IGF-1 receptor
[79]. The Castoria et al. laboratory has very recently
clarified the association of ER with both Src and PI3K in
MCF-7 cells [80]. The Src inhibitor, PP1, blocks 17h-
estradiol-induced activation of PI3K, while in turn the
PI3K inhibitor, LY294002, blocks the Src activation. More-
over, they show that, while ER can form complexes with
both signalling molecules in response to hormone treatment,
these binary complexes are weak and easily dissociate.
However, in vitro, a ternary complex of ER, Src and PI3K
induced by E2 is much stronger suggesting that in vivo, the
hormone will trigger a rapid association of all three leading
to a strong activation of both Src and PI3K (Fig. 2) [80].
2.8. Biological consequences of 17b-estradiol-induced
activation of Erk1/2
As mentioned previously, Erk1/2 has a wide variety of
cytoplasmic and nuclear targets, including a number of
transcription factors which Erk1/2 can activate by phos-
phorylation. To date, it has been shown that E2 is capable
of activating the transcription factors Elk-1, and as a result
c-fos, in MCF-7 cells, Egr-1 in cardiomyocytes and CREB
in adipocytes [57,81,82]. In each of these cases, Erk1/2
stimulation is required for hormone-induced activation of
the transcription factors. Once activated, these factors can
regulate the transcription of other genes; this allows estro-
gen to modulate the expression of genes that do not
contain classical estrogen response elements (ERE), thus
increasing the repertoire of biological effects of the sex
hormone (Fig. 2).
A second biological consequence of rapid activation of
Erk1/2 by E2 may be a modulation of the classical genomic
action of the hormone. Both ERs are also phosphoproteins
and to date, five phosphorylation sites, Ser104, Ser106,
Ser118 Ser167 and Tyr537 have been located on human
ERa (Ref. [83] and references therein). It has been sug-
gested that the phosphorylation of these residues promotes
the recruitment of co-activator proteins stimulating
increased transcription [84]. Growth factor (EGF and IGF-
1)-induced stimulation of the MAPK pathway triggers
phosphorylation of Ser118 and Ser167 on ERa leading to
stimulation of transcriptional activation [85,86]. Recently, it
has been shown that growth factor activation of MAPK
pathway also results in the phosphorylation of SRC-1, AIB1
and GRIP1, members of the SRC/p160 family of steroid co-
activators resulting in an increased rate of ER transcriptional
activity [87–89]. Because E2, itself, is capable of activating
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the MAPK pathway, it might be expected that hormone
induction of Erk1/2 may also result in similar phosphoryla-
tion events. There have in fact been some early reports of
rapid increases in phosphorylation of the ER in some cell
types following treatment with estrogen [90]. This rapid
phosphorylation should have the effect of priming the
genomic response by increasing the transcriptional activity
of the receptor. However, a detailed investigation into
estrogen-induced phosphorylation of both ER and the fam-
ily of steroid co-activators and its effect on rates of tran-
scription has not yet been performed (Fig. 2).
3. Na+–H+ exchanger: a target for rapid responses to
steroid hormones
3.1. Structure and function of Na+–H+ exchangers
The process of Na+–H+ exchange was first demonstrated
in intestinal and renal brush border vesicles in 1976 [91].
However, it was not until 1989 that the first gene encoding a
Na+–H+ exchanger (NHE) was identified and cloned [92]. To
date, six mammalian isoforms of the Na+–H+ exchanger
(NHE1 to NHE6) have been identified. The isoforms share a
similar hydropathy profile which indicates the existence of
two major structural domains: a hydrophobic transmembra-
nous N terminal responsible for catalysing Na+ and H+
exchange and a more variable hydrophilic C terminal
involved in regulation of the activity and subcellular distri-
butions of the exchangers [93]. NHE1 is ubiquitously
expressed at the basolateral membrane and plays a house-
keeping role in intracellular pH (pHi) and cell volume
regulation. In contrast, NHE2 to NHE6 have more limited
tissue distribution and specialized functions. NHE2 to NHE4
are abundant in epithelial cells of kidney, intestine and
stomach, whereas NHE2 and NHE3 are apically localised
and NHE4 is mainly basolateral. NHE5 is primarily
expressed in brain, spleen and testis. The most recently
identified isoform, NHE6, is only localised in mitochondria.
The antiporter, under normal conditions, catalyses the elec-
Fig. 2. Localisation of estrogen receptor (ERa) at the plasma membrane is required for rapid non-genomic activation of MAPK pathway. 17h-Estradiol binding
to ERa triggers an association with the signalling proteins Src kinase and PI3K at the plasma membrane. The formation of this complex has been shown to
activate signal transduction leading to stimulation of MAPK activity. A number of transcription factors are phosphorylated and activated by MAPK resulting in
the modulation of transcriptional events. While it has not yet been shown conclusively, hormone-induced activation of MAPK may also lead to phosphorylation
of ERa and a number of steroid co-activator proteins. The effect of this should be to enhance the genomic effects of ERa.
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troneutral exchange of one extracellular Na+ for one intra-
cellular H+. Na+–H+ exchange activity is essential for pH
homeostasis, cell volume regulation, transepithelial ion and
water transport, and plays a role in cell proliferation and
adhesion (see Ref. [94] for review).
3.2. Activation of NHE by steroid hormones
Steroid hormones have been shown to activate the
Na+–H+ exchanger in a wide variety of tissues including
epithelia, vascular smooth muscle and lymphocytes. Stim-
ulation of the Na+–H+ exchanger can influence the activity
of other ionic transporters, which in turn determine cell
volume, secretion and absorption. This section of the
review will focus on the effects of aldosterone and estro-
gen on the activity of the Na+–H+ exchanger.
It has long been known that hyperaldosteronism, resulting
in salt deprivation, stimulates Na+ absorption as well as K+
secretion, particularly in the late segments of the kidney
tubules and intestine [1]. These actions of aldosterone are
mediated by genomic—as well as non-genomic—pathways
and in distal nephron and intestine affect the electrogenic
transport pathways for Na+ absorption and K+ secretion.
Turnamian and Binder [95] have also demonstrated an
increase in electroneutral NaCl absorption, 1 day after aldos-
terone administration, in rat proximal and distal colon. The
same effects of aldosterone have been observed in rat
proximal colon [96]. Using specific inhibitors of the different
Na+–H+ exchanger isoforms, these authors have shown that
aldosterone stimulates Na+–H+ exchange by increasing
expression of NHE3 specifically. As NHE3 is known to be
the isoform involved in Na+ absorption, they concluded that
aldosterone regulates Na+ transepithelial movement in rat
proximal colon via activation of NHE3. It has been shown, in
VSMCs, that the genomic activation of the Na+–H+ anti-
porter was preceded by a rapid non-genomic activation. This
rapid activation was not blocked by inhibitors of de novo
protein synthesis, whereas the genomic effects, occurring
after 24 h, were suppressed [16]. These and other studies have
linked the nongenomic and genomic actions of aldosterone
and have suggested a two-step model for aldosterone effects.
Moura and Worcel [97] were the first to suggest a
nongenomic mineralocorticoid action by demonstrating an
increase of transmembrane Na+ flux in tail artery of adre-
nalectomized rats 15 min after injection of aldosterone. This
response was not suppressed by inhibitors of transcription
and translation. Since this study, rapid actions of aldosterone
on Na+–H+ exchange have been described in a wide variety
of cell types. Aldosterone activates the Na+–H+ exchanger
resulting in an increase in intracellular pHi in frog kidney
diluting segment [98]. As this stimulation was prevented by
the mineralocorticoid receptor antagonist, spirolactone, and
inhibitors of transcription and translation, the authors con-
cluded that this action was mediated by the genomic path-
way. Recent studies from our laboratory have demonstrated
rapid ( < 1 min) nongenomic activation of Na+–H+ ex-
changer in human and rat distal colon and sweat gland,
which was not affected by spirolactone [99,100]. Similar
results were obtained in both VSMCs and human mono-
nuclear leukocytes [101,102]. Rapid effects of aldosterone
on the Na+–H+ exchanger have been widely characterised
in Madin–Darby canine kidney cells (MDCK). Gekle et al.
[103] have shown that aldosterone initially activates a
plasma membrane proton (H+) conductance, which in turn
activates the Na+–H+ exchanger. These authors have pro-
posed that the aldosterone-sensitive H+ conductance main-
tains Na+–H+ exchange activity by providing an acidic
environment in the vicinity of the exchanger.
The most widely studied nongenomic effects of estradiol
are its action on intracellular Ca2 + and cAMP levels and on
PKC and MAPK activation with non-genomic effects of
estradiol on the Na+–H+ exchanger not being extensively
documented. E2 is essential for male fertility by enhancing
fluid reabsorption for concentrating sperm in the head of the
epididymis. Studies have shown that this action is due to the
regulation by E2 of the Na+–H+ exchanger isoform 3
(NHE3) and the rate of Na+ transport was sensitive to an
NHE3 inhibitor [104]. These effects are non-genomic as
they could not be inhibited by the classical estrogen receptor
antagonist, tamoxifen, or by inhibitors of transcription and
translation. In MCF7 cells, E2 up-regulates expression of
the Na+–H+ exchanger regulatory factor NHE-RF. NHE-RF
is a protein co-factor essential for PKA-mediated inhibition
of NHE3 and links NHE3 to the actin cytoskeleton. As
NHE-RF plays a critical role in endocytosis, internal traf-
ficking and targeting membrane proteins to the apical
membrane, estradiol regulates NHE3 activity by controlling
the number of exchangers at the plasma membrane [105].
An early report demonstrated a rapid activation of Na+–H+
exchange by E2 in rat pituitary cells with the responses
being insensitive to classical ER antagonists and inhibitors
of transcription and translation [106]. Recent studies from
our laboratory have demonstrated an increase in intracellular
pHi within 1 min after aldosterone and estradiol addition in
rat female distal colonic crypts. Inhibition of the alkaliniza-
tion by inhibitors of the Na+–H+ exchanger, amiloride and
EIPA, demonstrated that these steroids act on the Na+–H+
exchanger [8,107].
In our laboratory, the mechanisms of activation of the
Na+–H+ exchanger by aldosterone and E2 have been
investigated. Our studies have shown that the effects of
these steroid hormones on the antiporter are both miner-
alocorticoid and sex steroid hormone specific. The miner-
alocorticoid, fludrocortisone, and the glucocorticoids,
dexamethasone and hydrocortisone, did not activate the
Na+–H+ exchanger. Similarly, the sex-steroid hormones,
17a-estradiol, progesterone and testosterone did not induce
an alkalinization. Moreover, the stimulation of the anti-
porter by E2 is gender specific. We have shown that the
effects of estradiol could only be observed in female rat
distal colon. In contrast, aldosterone activates the exchanger
in both sexes.
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Aldosterone and E2 require PKCa to activate the Na+–H+
exchanger [8] (Fig. 1). We have shown that pre-incubation
with the PKCa inhibitor, HBDDE blocks the hormone-
induced activation of the antiporter. Gekle et al. [108] have
shown that non-genomic activation of the Na+–H+ exchanger
by aldosterone involves the MAPK pathway in MDCK cells.
The aldosterone-induced stimulation of the Na+–H+
exchanger activity was prevented by the two specific inhib-
itors of Erk1/2 activation, PD98059 and U0126. Mecha-
nisms, which link the stimulation of Erk1/2 to Na+–H+
exchanger activation in MDCK cells, are not yet known.
In pluripotential epithelia, such as intestinal tract, kidney
and sweat gland, intracellular alkalinization, following acti-
vation of the Na+–H+ exchanger, affects transepithelial ion
and water transport (Fig. 1). The Na+–H+ exchanger is
therefore a primary ion transport target of the non-genomic
signal transduction cascade induced by aldosterone and E2
(see Ref. [2] for review). The consequences of its activation
on transepithelial ion and water transport are discussed in
the subsequent section.
4. Non-genomic effects of steroid hormones on ion
transport in epithelia
The mineralocorticoid hormone aldosterone has been
identified as one of the major regulators in body fluid,
electrolyte, and pH homeostasis [109,110]. Classically,
aldosterone exerts its action on high-resistance epithelia,
such as kidney, distal colon, sweat and salivary glands, by
increasing the expression of epithelial sodium ion channels
(ENaC), potassium ion channels and Na+–K+-ATPases.
Sodium ion transport across the tight epithelia of reabsorb-
ing tissues is the major factor determining total-body Na+
and fluid levels, and thus, long-term control of blood
pressure [111]. However, upon treating target epithelia with
aldosterone, the beginning of the physiological response
precedes the accumulation of induced proteins, indicating
that there must be an earlier ‘‘regulatory’’ phase of aldoster-
one action that precedes the genomic phase.
4.1. Kidney
Regulation of sodium re-absorption in the kidney occurs
mostly in the distal nephron where re-absorption is a two-
step process as originally described by Ussing for frog
skin. Sodium enters renal cells from the luminal compart-
ment through ENaC in the apical membrane before it is
actively transported out of the cell by the basolateral Na+–
K+-ATPase. ENaC is usually the rate-limiting step for Na+
transport and, therefore, a key target in aldosterone action.
Classically, because of the observation that mRNA tran-
scription and protein synthesis are required for aldosterone
to increase sodium transport, it was hypothesized that
aldosterone induces ENaC synthesis and insertion in the
apical membrane. While the evidence from electrophysio-
logical measurements remains somewhat controversial
[112–114], most of the available biochemical evidence
suggests that the number of sodium channel proteins in
the apical membrane does not change after aldosterone
treatment, at least in the first 2–4 h when the increase in
sodium transport is most dramatic [115–118]. This sug-
gests that aldosterone can also regulate sodium transport by
a rapid mechanism in the nephron. The post-translational
modification of the channels that increases their open
probability, offers an alternative pathway for the rapid
aldosterone action. Zhou and Bubien [119] demonstrated
rapid ( < 2 min) aldosterone-induced activation of ENaC in
principal cells from the renal collecting ducts, this effect is
sensitive to inhibitors of methyl esterification suggesting
methylation of one of the ENaC subunits by methylases.
Previous reports by Sariban-Sohraby et al. [120] showed
that application of aldosterone also leads to the methylation
of membrane proteins. However, neither of the ENaC sub-
units contains methylation consensus sequences. Thus,
another protein must be methylated which in turn activates
ENaC. The link between methylation and ENaC activation
was found recently when Al Baldawi et al. [121] and
Stockand et al. [122] demonstrated that K-Ras2A protein
is a target for methylation and that its methylation is
induced by aldosterone in A6 distal nephron cells. These
studies do not clearly show the mechanism(s) by which K-
Ras activates ENaC. The simplest mechanism would be
direct ENaC/K-Ras interaction. However, it is likely that
there are other signalling elements that lie between Ras and
ENaC. The traditional effector of Ras is Raf kinase, Raf
activation leads to activation of the MAPK pathway.
However, activation of MAPK pathway appears to inhibit
ENaC activity rather than stimulate it. Nevertheless, rapid
aldosterone-induced activation of Na+–H+ exchanger
(NHE) in MDCK cells [108] and M1 cortical collecting
duct cells (unpublished data) are a MAPK-dependent
process (Fig. 2).
Activation of ENaC is not the only event elicited by
aldosterone to increase sodium absorption. Active transport
of sodium in the basolateral membrane not only requires the
activity of Na+–K+-ATPase but also potassium recycling
through basolateral potassium channels. It has been demon-
strated in principal frog skin cells that aldosterone induces
rapid activation of ATP-sensitive potassium channels (KATP)
[123]. The time course for the rapid activation of KATP
channels is similar to the rapid ENaC activation time (< 2
min). This effect is dependent on previous activation of
NHE and intracellular pH alkalinization; KATP channels are
highly sensitive to variations in intracellular pH within the
physiological range (7.0–7.5). The role of aldosterone-
induced activation of KATP channels is to preserve the
driving force for Na+ absorption by acting as a ‘‘physio-
logical voltage-clamp’’ which compensates membrane
depolarisation producing by Na+ entry into the cell [123].
Fig. 3 illustrates the pro-absorptive mechanism of aldoster-
one in kidney.
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4.2. Distal colon
The mammalian colon is a major target for aldosterone,
and the level of mineralocorticoid receptor gene expression
is higher in the distal colon than in any other target tissue
including the kidney [124]. In the distal colon, aldosterone
causes a switch from electroneutral NaCl absorption to
stimulated electrogenic Na+ absorption by inducing expres-
sion of apical ENaC and basolateral Na+–K+-ATPase
[125]. In parallel, net K+ absorption is converted to net
K+ secretion by induction of apical K+ channels. This
process has been well characterized; however, several
studies have demonstrated that changes in electrolyte
transport precedes the increase in induction of these
proteins. Early studies in the 1970s reported rapid effects
of aldosterone on ion transport in rabbit distal colon [126].
Aldosterone induced a rapid ( < 30 min) increase in the
short-circuit current (Isc), an equivalent increase in the rate
of active Na+ absorption ( JNa net) and a decline in tissue
resistance (Rt). Aldosterone produced no change in Na
+–
K+-ATPase protein number or activity within the time
frame of these studies. Also, aldosterone had no effect
on the bi-directional or net transepithelial movements of
K+ under short-circuit conditions, suggesting that the
enhanced secretion of K+ observed in vivo is the result
of increased diffusion of K+ from plasma to lumen via
paracellular pathways in response to an increased trans-
epithelial electrical potential difference (lumen negative).
More recently, it has been found that aldosterone also
regulates basolateral potassium channels in rat distal colon
[7]. These channels are responsible for potassium recycling
in the basolateral membrane and play an essential role in
sodium absorption and chloride secretion [125]. Basolateral
potassium channels in colonic epithelia are very sensitive
to changes in intracellular pH within the physiological
range [7]. In the rat distal colon, aldosterone induces rapid
activation of NHE that leads to intracellular alkalinization.
This change in intracellular pH has a significant impact on
basolateral potassium conductances producing activation of
KATP channels and inhibition of a calcium-dependent
Fig. 3. Schematic diagram of the non-genomic aldosterone signalling pathway in kidney. The schematic is based on the observations that aldosterone-induced
activation of sodium transport requires activation of methyl transferase to methylate K-Ras2A, and stimulation of SAH-hydrolase to eliminate inhibition of
methyl transferase by SAH. Possible effectors for K-Ras2A are Raf-Kinase (Raf-K), which in turn can activate MAPK pathway, and 4-PIP-5 that mediates
4,5-PIP2, a strong activator of ENaC. MAPK activation stimulates NHE activity.
B.J. Harvey et al. / Biochimica et Biophysica Acta 1566 (2002) 116–128 125
potassium channel (KCa) [7,123]. Previous studies have
demonstrated that KATP channels are involved in electro-
genic Na+ absorption in distal colon [7,107,127]. This
result suggests that aldosterone’s non-genomic action will
lead to a rapid increase in Na+ absorption. In contrast to
rabbit tissue, there are no reports of rapid activation of
ENaC in rat distal colon; this is consistent with previous
studies that reported lack of rapid ENaC activation in mice
and rat kidney cells [119]. Therefore, it appears that the
activation of KATP channels will not increase Na
+ absorp-
tion by itself but will counteract membrane depolarisation
produced by Na+ entry into the cell during the genomic
phase of aldosterone action.
On the other hand, KCa channels are involved in
electrogenic chloride secretion. The molecular identity of
KCa channel remains unknown but they have been char-
acterized pharmacologically. This channel is sensitive to
quaternary ammonium salts (tetrapentyl and tetraethyl
ammonium) and partially blocked by barium [7]. Inhibition
of this channel leads to a decrease in basolateral potassium
recycling, thus producing reduction in chloride secretion.
Similar effects on basolateral potassium conductance were
found following 17h-estradiol application [127]. 17h-
Estradiol was shown to have anti-secretory effects on basal
and stimulated cAMP-dependent (forskolin) or Ca2 +-
dependent (carbachol) chloride secretion [3]. Also, pre-
treatment of the tissues with 17h-estradiol for 10 min
prevented the effect of forskolin and carbachol [3]. 17h-
Estradiol is PKC dependent and sensitive to calcium
chelation. Also, this effect is gender specific since it was
not observed in male rats. It is possible that this gender-
specific mechanism contributes to the salt and water
retention associated with high estrogen states. Therefore,
the non-genomic action of aldosterone and 17h-estradiol
(in female) in the distal colon leads to an up-regulation of
sodium absorption while down-regulating the capacity for
chloride secretion (Fig. 1).
4.3. Airway epithelium
In airway epithelium glucocorticoid, non-genomic effects
on intracellular calcium have been characterized [128]. As
in the kidney and colon, the mechanism of chloride secre-
tion requires a basolateral potassium conductance to provide
the driving force (ref). However, further experiments are
needed to analyse the role of glucocorticoid non-genomic
action on ion transport in the lung.
5. Conclusions
Our current knowledge of non-genomic action of steroid
hormones in epithelia points to a role for rapid regulation of
ion transport. The physiological function of non-genomic
effects is to shift the balance from net secretion to net
absorption in pluripotential epithelia. To achieve this effect,
several pathways are activated, such as PKC, PKA, MAPK,
intracellular calcium and pH. Initially, PKC appeared to be a
common pathway for rapid responses to steroid hormones.
However, now it is clear that activation of specific PKC
isoforms confers selectivity to steroid hormone action. Non-
genomic and genomic actions may even synergize, leading
to the appearance of biphasic effects that have both a rapid
onset and a long-lasting persistence. A better knowledge of
non-genomic actions of steroids is likely to open new
perspectives in the understanding of animal and human
physiology, as well as in the pharmacological treatment of
some pathological conditions.
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